Drug Target Review

Targeting mGlu7 could lead to new anxiety and PTSD treatments

Explore innovative anxiety and PTSD treatments with Addex Therapeutics' groundbreaking research on mGlu7 modulators.

Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment

Data published in Molecular PsychiatryAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026-Addex Therapeutics (SIX: ...